Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down
13/9 05:51
(RTTNews) - Cidara Therapeutics Inc. (CDTX) has announced a reduction in its workforce by approximately 30% to concentrate on advancing the clinical development of CD388, the company's innovative DFC candidate targeting influenza A and B....